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Summary Despite the clear progress achieved in recent
years in the treatment of MM, most patients eventually
relapse and therefore novel therapeutic options are still
necessary for these patients. In this regard, several drugs
that target specific mechanisms of the tumor cells are
currently being explored in the preclinical and clinical
setting. This manuscripts offers a review of the rationale
and current status of the antimyeloma activity of one of the
most relevant examples of these targeted drugs: deacetylase
inhibitors (DACi). Several studies have demonstrated the
prooncogenic activity of deacetylases (DACs) through the
targeting not only of histones but also of non histone
proteins relevant to tumor progression, such as p53, E2F
family members, Bcl-6, Hsp90, HIF-1α or Nur77. This fact
together with the DACs overexpression present in several
tumors, has prompted the development of some DACi with
potential antitumor effect. This situation is also evident in
the case of MM as two mechanisms of DACi, the inhibition
of the epigenetic inactivation of p53 and the blockade of the
unfolded protein response, through the inhibition of the
aggressome formation (by targeting DAC6) and the
inactivation of the chaperone system (by acetylating HSP-
90), provides the rationale for the exploration of the
potential antimyeloma activity of these compounds. Several
DACi with different chemical structure and different
selectivity for targeting the DAC families have been tested
in MM. Their preclinical activity in monotherapy has been
quite exciting and has been described to be mediated by
various mechanisms: the induction of apoptosis and cell cycle
arrest mainly by the upregulation of p21; the interferece with
the interaction between plasma cells and the microenviron-
ment, by reducing the expression and signalling of several
cytokines or by inhibiting angiogenesis. Finally they also
have a role in protecting murine models from myeloma bone
disease. Neverteless, the clinical activity in monotherapy of
these drugs in relapsed/refractory MM patients has been very
modest. This has prompted the development of combinations
such as the one with bortezomib or lenalidomide and
dexamethasone, which have already been taken into the
clinics with positive preliminary results.
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Introduction
Multiple Myeloma (MM) is a B cell malignancy character-
ized by the presence of bone marrow infiltration by clonal
plasma cells that generally secrete a monoclonal component
in the serum or urine [1]. It is the second most frequent
haematological malignancy, after non hodgkin lymphomas,
and accounts approximately for a 10% of all haematolog-
ical tumors and 1% of all cancers [2]. Treatment of MM has
remained substantially unchanged for some time (reviewed
in [3]) with alkylating agents such as melphalan in
combination with steroids being the gold standard for more
than 25 years. Later on, in the 1970 decade, other drugs
such as carmustine or vincristine where combined with
melphalan, cyclophosphamide or steroids giving rise to the
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polichemotherapeutic regimens; and 10 years later high
doses of melphalan with autologous stem cell transplanta-
tion (ASCT) where introduced into the clinical practice. All
these treatment schemes resulted in an overall survival of
around 30 months until 1994 with a slight improvement in
the subsequent 5 years, probably due to the introduction of
ASCT and better measures of supportive care [4]. Finally,
in the first decade of this century, some new drugs with
novel mechanisms of action and clear antimyeloma activity
have been discovered and approved. In this regard, several
studies have demonstrated the activity of the proteasome
inhibitor bortezomib [5] and the immunomodulatory agents
thalidomide [6] and lenalidomide [7, 8] in relapsed/
refractory MM patients. The emergence of these drugs has
resulted in a clear improvement in the outcome of these
patients in the last years, with an increase in median overall
survival of up to 5 years [4].
Nevertheless, despite this clear progress, most patients
(if not all) eventually relapse and therefore novel therapeu-
tic options are still necessary for these relapsed or refractory
patients. In this regard, several drugs that target specific
mechanisms of the tumoral cells are currently being
explored in the preclinical and clinical setting [9, 10].
Some examples of these targeted agents are second-
generation proteasome inhibitors or immunomodulatory
agents, inhibitors of the PI3K/AKT/mTOR pathway, heat
shock protein inhibitors, several monoclonal antibodies
against surface antigens such as CS1 and deacetylase
inhibitors (DACi), the focus of this review.
Concept and classification of DACs and DACi
Deacetylases (DACs) are enzymes specialized in remov-
ing acetyl groups from their target proteins. As histones
were formerly considered the main client proteins for
DACs, these enzymes are sometimes known as histone
deacetylases (HDACs) [11, 12] but we currently know
that DACs have a dual role; on one side, they have the
epigenetic regulatory function, which is exerted by
controlling the delicate balance between acetylation and
deacetylation of histones that control the accessibility of
the chromatin to transcription factors [11]. On the other
hand, many other non-histone proteins such as α-tubulin,
p53, p73, retinoblastome, several steroid receptors, E2F
family members, Bcl-6, Hsp90, HIF-1α or Nur77 among
others, are also deacetylated by DACs; in fact, more that
50 non-histone proteins have been described to be
substrates of DACs [12].
Based on their homology with yeast proteins DACs have
been typically classified into four groups: [13, 14] class I, II
and IV DACs are called classical DACs, whereas class III
DACs are called sirtuins due to their of homology to yeast
Sir2, and display characteristic features, such as the
requirement of NAD+ as an essential cofactor for their
activity, and the absence of Zinc in the catalytic site [11,
13]. The classical DACs are the ones that have been
implicated in oncogenesis and are targets of the DACi
currently used in the clinic so we will mainly focus in these
three types of DACs. Class I DACs includes DAC1, DAC2,
DAC3 and DAC8. They are commonly restricted to the
nucleus of the cells [15–17] and their most relevant
substrates are proteins such as p53, MEF2D, Stat3 or E2F.
Class II DACs can be further subdivided into class IIA and
IIB, which display different targets and localization. Class
IIA are both nuclear and cytoplasmic DACs and include
DAC4, DAC5, DAC7 and DAC9. The class IIB are
probably more important and contains the cytoplasmic
DAC6 and DAC10. The first one has been described to be
very important in tumour pathogenesis and specifically in
MM mainly due to their activity on two relevant substrates,
α-tubulin [18, 19] and Hsp-90 [20]. Therefore, as we will
review later in the manuscript, the inhibition of this DAC
may have a significant role in the treatment of MM. The
last type of classic DAC are class IV DACs, whose only
representative is DAC11 whose function and role in
oncogenesis has not been well described yet.
Several factors have prompted the use of DACi in the
treatment of cancer: First, the increasing importance given
to epigenetic modifications in the pathogenesis of cancer
[21] and the role that changes in the activity of the some
non-histone substrates of DACi also play in oncogenesis.
Moreover, in support of this, significant changes in the
expression of DACs have been described in different
tumors. For instance, class I DACs, principally DAC 1, 2
and 3, are overexpressed in gastrointestinal and prostatic
tumors [22–25] and this is associated with an adverse
prognosis. Class IIA DACs expression has been shown to
be also upregulated in different tumors: DAC 4 in breast
and DAC 5 and DAC 7 in colorectal cancer [26]. Regarding
DAC6 it is significantly overexpressed and is associated
with advance stage in oral squamous cell carcinoma [27].
By contrast, the upregulation of its expression in breast
cancer has been described to confer a better prognosis [28,
29]. A second important reason that specifically supports
the use of HDACi in haematological malignancies is that
functional changes in these DACs have been described in
several leukemias and lymphomas. In this regard, DACs are
frequently involved in some oncogenic translocations
present in these diseases; the AML-1-ETO translocation,
characteristic of M2 acute myeloid leukemia modulates
repressive cofactors such as histone deacetylases (HDACs)
and DNA methyltransferases (DNMTs) [12, 30–32]. Both
DAC3 and DAC4 are recruited by the PML/RARα
translocation in acute promyelocytic leukemia, and collab-
orate in the repression of transcription that provokes the
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loss of differentiation characteristic of this type of leukemia
[33, 34].
Regarding myeloma the activity of DACs on several
non-histone proteins provides a good rationale for the use
of these compounds in this disease. This is the case of p53
that is considered a very important tumor suppressor gene
for all malignancies, but specifically for multiple myeloma.
In fact TP53 deletion, that hampers the transcription of
functional protein [35], is one of the main adverse
prognostic factors in this disease [36–38]. Moreover, the
antimyeloma activity of some drugs has been, at least in
part related to the increase in the protein levels of p53 [39].
This data together with the fact that the reversal of the
epigenetic inactivation of this protein has also been
demonstrated to induce apoptosis [40] points out p53 as a
potential relevant antitumoral target mechanism for DACi
in MM. Another pathogenetic mechanism in MM is the
unfolded protein response. This mechanism allows the
correct management of the great amount of proteins
synthesized by tumor cells. This situation is critical in
MM as this disease is defined by the proliferation of plasma
cells, which are characterized by the secretion of high
quantities of a protein, the monoclonal immunoglobulin.
For this purpose the cell requires the correct functionality of
the molecular chaperone HSP-90 (Heat Shock Protein-90)
that allows the correct folding of the synthesized proteins
into their spatial conformation [41, 42]. When this
mechanism is overloaded, there is an increase in misfolded
proteins that have to be degraded by the proteasome
through their previous ubiquitination. Nevertheless, those
misfolded proteins, which cannot be degraded by the
proteasome form stable aggregates that are toxic to the
cell. An alternative system to the proteasome for degrada-
tion of poliubiquitinated misfolded proteins, termed the
aggresome has been recently described [43, 44]. DAC6
facilitates the interaction between this aggregates and the
dynein motors in order to form the aggresomes [45] that are
structures that eliminate this toxic proteins from the cell. As
we have seen before, DACs have an important role in this
unfolded protein response at least through two different
pathways: the deacetylation of HSP-90 that allows its
correct functioning and the formation of aggresomes by
DAC6, and therefore its inhibition with DACi could have a
role in MM treatment.
All these data has stimulated the investigation of DAC
inhibitors as potential anticancer drugs and several of these
molecules are already at different stages of preclinical and
clinical development. Nevertheless, not all these DACi
under development have the same properties, in fact they
can be divided into different groups according to their
chemical structure and their pattern of DAC inhibition [12,
14, 15, 46, 47]. The first group of agents to be used as
DACi are aliphatic acids. It includes agents that have
previously been used in the clinic for other indications
based on other mechanisms of activity. The most important
ones are valproic acid, phenylbutyrate or butyrate. They
mainly inhibit class I DACs but may have some effect on
class II A HDACs. Neverteless, their potency of inhibition
of DAC is quite low and therefore their clinical activity has
not been very important. Two classes of DACi are quite
specific of the nuclear class I DACs with very scarce or no
effect over the cytoplasmic DACs. These are cyclic
peptides, with romidepsin (FK-228) being the most signif-
icant representative of this group. The second group is
constituted by benzamides such as entinostat (MS-275) or
MGCD0103. Hydroxamates are derivatives of the hydroxa-
mic acid and are characteristically pan-DACi because they
inhibit both class I and II HDACs. Due to its potency and
breadth of activity and the potency of its components, this
is the group with a more extensive development. It includes
molecules such as vorinostat (SAHA), panobinostat
(LBH589), TSA (Trichostatin A), belinostat (PDX-101),
resminostat (RAS2410), LAQ824 or ITF2357. A different
small molecule that does not fit into any of the previous
classes is tubacin, which was recently described as an
specific inhibitor of DAC6 [48] and induces acetylation of
tubulin and Hsp-90, without affecting histone acetylation.
Antimyeloma activity of DACi in monotherapy
Preclinical data and mechanisms of action of DACi in MM
Based on the previous data, several studies have explored
the in vitro and in vivo activity of different DACi as single
agents in MM. This is the case of vorinostat [49, 50],
sodium butyrate and trichostatin A [51], LAQ824 [52],
depsipeptide [53], valproic acid [54–57], panobinostat [58–
60], belinostat [61], R306465 [62], KD5170 [63], JNJ-
26481585 [64], ITF2357 [65] or resminostat [66]. Regard-
ing the mechanism of action of DACi in MM, these
compounds act through the induction of apoptosis mainly
by a caspase dependent mechanism but also a caspase
independent apoptotic mechanism has been described for
some of them [49, 56, 59]. Interestingly, a cell cycle arrest
in G0/G1 phases has been demonstrated as a very common
effect of most DACi analyzed. This effect seems to be, at
least partially mediated through the upregulation of the
tumor suppressor gen p21, mechanism that has been
observed with most of the DACi analyzed independently
of the type and pattern of DAC inhibition [49, 51, 57, 59,
62, 64, 66, 67]. This p21 deregulation has also been
associated with a decrease in the levels of some prolifer-
ative proteins such as cyclin D [54, 66], Cdk4 [66] or pRb
[49, 51, 66]. The homogeneity observed with these drugs in
the cell cycle regulation through p21 modifications
S30 Invest New Drugs (2010) 28 (Suppl 1):S28–S35
suggests that it may be a class specific effect of DACi in
MM cells, and probably all tumor cells. A parallel
mechanism which may be related to the previous one is
the interference with the pAKT pathway that has been
demonstrated by the decreased phosphorylation of 4E-BP1
and p70S6k, and that has been recently described with
resminostat [66]. This blockade of the AKT pathway also
leads to a reduction in proliferation of tumor plasma cells.
Two DACi with different chemical structure, belinostat and
KD5170 have also been shown to induce DNA damage as
assessed by H2AX phosphorylation [61, 63]. This effect
was preceded by the induction of oxidative stress with
generation of reactive oxygen species and a subsequent
release of mitochondrial mediators of apoptosis.
As important as the discovery of the mechanisms of
action of a drug or type of drugs is the detection of potential
mechanisms of resistance for these compounds. A second
mechanism for DACi, which has mainly been observed in
hydroxamate-derived compounds, is the modulation of
several bcl-2 family members leading to a proapoptotic
phenotype. In this regard, several studies have demonstrat-
ed that treatment with these drugs induces a downregulation
of several antiapoptotic member of this family of proteins,
mainly Bcl-2 and Bcl-X. This has been the case of
vorinostat [49, 67, 68], panobinostat [59], depsipeptide
[53] or trichostatin [67]. Moreover, treatment with vorino-
stat has been associated with an increase in the expression
of some proapoptotic BH3-only proteins such as Bim, Bak,
Bax, Puma and Noxa [67, 69]. Interestingly, the over-
expression of some of these antiapoptotic proteins was able
to prevent DACi induced cell death. In this regard, the
overexpression of Bcl-X in MM cells inhibited panobino-
stat induced apoptosis [59], and transfection of Bcl-2
cDNA into MM cells completely abrogated the activity of
vorinostat [49]. These observations clearly indicate the
relevant importance of the modulation of Bcl-2 family
members in the activity of DACi and point out to a possible
mechanism of resistance of the cells to these treatments.
A very important player in MM pathogenesis is the
interaction of the tumor cells with the microenvironment. In
fact this interaction through direct contact or through the
secretion of cytokines triggers the activation of different
signaling pathways such as the PI3K/AKT, MAPK/MEK/
ERK or JAK/STAT pathways, that ends up in a proliferative
advantage for myelomatous plasma cells and a drug
resistance phenotype [70, 71]. As a consequence, in the
last years, there has been an increasing interest in
developing novel treatments that could act not only on the
tumor cell, but also on the microenvironment and on the
interactions between these two factors. Several preclinical
results suggest that DACi have a role in blocking this
mechanism in different ways. First, panobinostat and LAQ-
824 are able to kill MM cells even when they are
cocultured with stromal cells [52, 58]. Regarding the effect
of DACi on cytokines, ITF2357 downregulated the receptor
alfa of IL-6 leading by a decreased signaling as measured
by STAT-3 phosphorylation in the presence or absence of
IL-6 [65]. Moreover, GEP analysis of changes induced after
vorinostat treatment indicated that this drug downregulated
transcripts for members of the Insulin-like growth factor/
insulin-like growth factor-1 receptor (IGF/IGF-1-R) and IL-
6 receptor [50], and functional experiments showed that this
same drug inhibited the secretion of IL-6 induced in by the
bone marrow stromal cells after binding to MM cells [49].
Two other factors to be taken into account when
analyzing the role of the microenvironment in MM are
angiogenesis, and MM bone disease, which is one of the
most debilitating symptoms for these patients and results
from the disruption of the delicate equilibrium between
formation of bone by osteoblasts and the bone resorption
induced by osteoclasts. Regarding these two aspects,
treatment of 5T2MM-bearing mice with JNJ-26481585
resulted in a significant decrease in angiogenesis and a
significant reduction in the development of bone disease
[64]. In the same line, panobinostat was able to decrease
trabecular bone density loss in a model of disseminated
myeloma [60]. Valproic acid also has antiangiogenic effect
as assessed by the inhibition of the production of vascular
endothelial growth factor [54], and the inhibition of
vascular tubule formation enhanced by the co-culture of
MM cells with osteoclasts [56]. Finally, treatment with this
drug also suppressed osteoclastogenesis and osteoclast-
mediated MM cell growth [56].
Clinical
Four studies have analyzed the activity of DACi as single
agents in phase I/II trials in relapsed/refractory MM
(Table 1). All of them included small numbers of patients
which were quite refractory to their previous therapies. The
DACi Reference Phase n ORR Responses
Panobinostat Wolf 2008 [72] II 38 3% 1PR, 1 MR, 1 SD
Vorinostat Richardson 2008 [73] I 13 10% 1 PR, 9 SD
ITF2357 Gally 2010 [74] II 19 7% 1 PR, 1 SD
Romidepsin Niesvizky 2005 [75] II 12 0% 11 SD
Table 1 Summary of the most
relevant results of clinical
trials with DACi in
monotherapy in MM
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results show that, despite their preclinical activity, the
clinical efficacy of all these drugs, when used in mono-
therapy, was quite modest.
Panobinostat monotherapy was explored in a phase II trial in
38 patients who had received at least 2 prior lines of therapy
(including bortezomib and lenalidomide or thalidomide) and
who were also refractory to their most recent line of therapy.
Among them one patient achieved a durable VGPR and
another one a durable MR; in addition three patients achieved
disease stabilization. Overall, panobinostat was well tolerated,
with half of the patients suffering from GI symptoms as well as
fatigue/asthenia and cytopenias [72]. In a phase I trial of
escalating doses of oral vorinostat, 13 patients were enrolled
with one of them achieving minimal response and nine stable
disease. The most frequent drug-related adverse events were
mostly mild and included general symptoms (fatigue, anorex-
ia) and GI symptoms (dehydration, diarrhea, and nausea) [73].
A phase-II trial of the oral DACi ITF2357 was performed in
19 patients with relapsed or progressive MM with oral
dexamethasone allowed to a maximum weekly amount of
20 mg. No patients responded with 5 of them showing stable
disease. The most frequent toxicities were GI, transient
electrocardiographic abnormalities and thrombocytopenia
[74]. Finally, the cyclic peptide romidepsin has also been
explored in monotherapy in a phase II trial in MM patients
with documented progressive disease. Twelve patients with
relapsed or refractory MM were treated. Eleven out of the 12
patients had stable disease (SD) with similar toxicity to that
reported with the previous DACi [75].
Combinations of DACi
In spite of the rather disappointing results obtained with DACi
used as single agents in the relapse/refractory setting, the
observation of disease stabilization and some responses,
together with the in vitro data showing marked synergism in
combination with other antimyeloma agents, set up the basis
for the investigation of the role of DACi in combination
therapies (Table 2).
The rationale for the combination of DACi with proteasome
inhibitors relies in a mechanism that has been previously
described in this review: the simultaneous targeting of several
proteins involved in the unfolded protein response. By blocking
the proteasome with specific inhibitors we block the degrada-
tion of the ubiquitinated misfolded proteins by this organelle,
while the use of DACi interfere with the activity of heat shock
proteins, necessary for the correct folding of proteins, and with
the aggressome formation (through the inhibition of DAC6)
which is also important in the elimination of toxic misfolded
proteins. Therefore, the simultaneous blockade of this three
survival mechanisms would end up in a synergistic cytotoxic
effect. In this regard, several studies have demonstrated the
potentiation of the activity of DACi with bortezomib [58, 60,
61, 63, 66, 76–79] and this potentiation was even stronger
when associating dexamethasone [60]. Interestingly, a signif-
icant deregulation of genes involved in cell cycle arrest,
apoptosis and other pathways such as chemotaxis or adhesion
were observed after treatment with the triple combination with
bortezomib and dexamethasone when compared to these
agents in monotherapy [60]. Two phase I trials with vorinostat
in combination with bortezomib have been reported [80, 81]
including 23 and 34 patients, with an ORR of around 40%.
Interestingly, the combination was able to induce responses in
patients that had relapsed or had been previously refractory to
bortezomib. In this regard, in the first study three PR were
observed in 9 bortezomib refractory patients [80], and in the
second one, among 13 patients previously exposed to
bortezomib 5 achieved PR, 1 MR and 7 SD [82]. Panobino-
stat has also been combined with bortezomib in this relapsed/
refractory setting in a phase Ib trial that included 29 patients.
The ORR was 48% [83] with some patients achieving CR.
This combination was also effective in 10 bortezomib
refractory patients with 4 PR and 2 MR. The third DACi
that has been combined with bortezomib is the cyclic peptide,
romidepsin [84]. Twenty five patients were included in this
Table 2 Summary of the most relevant results of clinical trials with DACi in combination with other agents in MM
DACi Combination Reference Phase n ORR Responses
Vorinostat Bortezomib Badros 2009 [80] I 23 42%
Vorinostat Bortezomib Weber 2008 [81] I 34 43% 10%VGPR, 33%PR, 48%SD
Vorinostat Bortezomib Weber 2008 [82] I 13a 38% 38%PR, 8%MR, 54% SD
Panobinostat Bortezomib San Miguel 2009 [83] Ib 29 48% 14%CR, 34%PR, 14% MR
Romidepsin Bortezomib Harrison 2008 [84] I 25 67% 22%CR, 22% VGPR, 22%PR, 28%MR
Vorinostat Pegylated Lip. Dox + Bortezomib Voorhees 2009 [85] I 11 63% 9%CR, 27%VGPR, 27%PR
Panobinostat Lenalidomide + Dex Spencer 2009 [86] Ib 13 45% 8%sCR, 8%CR, 30%VGPR
Vorinostat Lenalidomide + Dex Siegel 2009 [87] I 28 46% 7%CR, 39%PR, 18%MR, 21%SD
Panobinostat Melphalan Berenson 2009 [88] I 15 27% 7%CR, 20% VGPR
aAll patients were previously exposed to Bortezomib
S32 Invest New Drugs (2010) 28 (Suppl 1):S28–S35
study and an ORR of 67% was observed. Two-thirds of these
responses were of good quality (CR or VGPR), figure that is
important in this setting of relapsed/refractory patients.
Regarding toxicity, the combination of DACi and bortezomib
was overall well tolerated, with general and GI symptoms
probably derived from the use of the DACi, and with
reversible thrombocytopenia as the main specific toxicity of
the combination. It is interesting to remark the promising
activity on patients previously exposed to bortezomib, which
highlights the synergy of the combination and the possibility
to overcome bortezomib refractoriness. A further step was to
add pegylated liposomal doxorubicine to this combination.
Although numbers are very small, a clinical trial using this
triple combination in 11 relapsed/refractory patients, most of
them previously exposed to bortezomib and anthracyclins,
showed 63% ORR with more than one-third of patients
achieving VGPR or better [85].
A second interesting combination is the one with the
immunomodulatory drug lenalidomide and dexamethasone.
There are some in vitro results that support this association
with combination indexes in the very high synergistic range
[60]. Similarly to what has been said for the combination
with bortezomib and dexamethasone, there is a transcrip-
tomic rationale behind the synergy of this combination with
a completely different array of genes deregulated by the
triplet as compared to sum of the genes deregulated by the
agents in monotherapy [60]. Both panobinostat and
vorinostat have been combined with lenalidomide and
dexamethasone in two phase I clinical trials [86, 87]. Both
trials showed an ORR of around 45% with some patients
achieving good quality responses: 7% CR in the combina-
tion with vorinostat and 46% of VGPR or better for the
combination that included panobinostat. Moreover, in the
trial with vorinostat, among 12 patients that had received
previous lenalidomide, four patients achieved PR or MR
and 3 SD. The most frequent adverse effects for these
combinations included general symptoms and GI symptoms
such as diarrhoea, and also myelosuppression with different
cytopenias (thrombocytopenia and neutropenia).
One last combination that has recently been tested is the one
of panobinostat and melphalan. This combination showed one-
third of responses in a phase I trial that enrolled 15 relapsed/
refractory MM patients, the majority of whom had previously
been exposed tomelphalan. In fact, all responses were observed
in melphalan treated patients [88].
Conclusions
The solid preclinical rationale for the use of DACi in MM
as well as the good positive clinical results, particularly in
combination with other agents such as bortezomib or
lenalidomide, suggest that this class of drugs may reach
approval as antimyeloma agents. In this time, phase III
randomized trials are underway in order to prove if the
combination of DACi with either bortezomib or lenalido-
mide plus dexamethasone are superior to the standards used
at present for relapsed/refractory patients.
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